Selecting the right clinical research site is critical to the speed, quality, and success of your trial. Whether you represent a pharmaceutical sponsor, CRO, functional food company, or clinical site network, we have compiled clear answers regarding our capabilities, response timelines, site infrastructure, and study execution standards.
Direct executive response guaranteed within 16 business hours.
The execution of clinical research is our 100% core competence and sole business activity. We do not engage in external patient care or unrelated medical services. This total focus guarantees that every study receives top operational priority: rapid participant recruitment, strict target compliance, dedicated subject care, seamless monitor support, and prompt query resolution.
EB Medical Research (EBMR, operating legally as EB FlevoResearch B.V.) is a dedicated clinical research site fully equipped to execute Phase II–IV pharmaceutical trials, vaccine studies, and specialized human intervention trials. Thanks to our flexible site infrastructure and experienced research nurses, we rapidly adapt to diverse protocol requirements.
While we welcome studies across a wide range of general and specialty medicine, our proven track record includes extensive experience in:
Metabolic & Endocrine: Type 2 Diabetes Mellitus (T2DM), Obesity, and complex multi-indication trials (e.g., overweight combined with cardiovascular or renal comorbidities).
Cardiovascular & Renal: Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) patient populations.
Vaccines & Infectious Diseases: Influenza, Urinary Tract Infection (UTI), and general vaccine studies.
Specialized Areas: Chronic Pain, Women’s Health, and Health Technologies.
If your specific indication is not listed, our executive team provides a tailored feasibility assessment within 16 business hours.
EB Medical Research brings over 20 years of continuous clinical trial experience with GLP-1 receptor agonists and incretin-based therapies. Beginning with early-stage T2DM studies, our expertise has evolved to include pure Obesity protocols and complex trials evaluating overweight in combination with comorbidities such as CVD, CKD, and Asthma. We maintain a large, active pool of candidate participants in this domain.
Beyond regulatory compliance and health claims, conducting a clinical study provides deep scientific insight into how products—and their individual active components—behave within the human body.
Participating in GCP-compliant human intervention studies allows R&D and innovation teams to:
Drive Next-Generation Product Development: Use evidence-based data to optimize formulations, improve active dosages, and develop superior new products with targeted health outcomes.
Substantiate Health Claims: Build robust scientific evidence required for EFSA/FDA claim approvals and regulatory compliance.
Establish Commercial Credibility & Trust: Differentiate products in a crowded marketplace with peer-reviewed, gold-standard human trial data that instills confidence in consumers, retailers, and healthcare professionals.
De-Risk Innovation Launches: Validate efficacy, safety, and active mechanisms before committing to full-scale commercial rollouts.
EBMR is one of the few dedicated clinical sites in the Netherlands with deep expertise in executing human intervention studies for the functional food, dairy, and dietary supplement industries. We have successfully completed trials involving up to 140 participants, evaluating probiotics, protein formulations, specialized nutrition, and dietary ingredients. Our flexible pool of experienced Research Nurses allows us to scale rapidly for high-volume participant visits and intensive study schedules.
Our clinical facility in Almere is fully equipped for intensive trial monitoring, safety assessments, and extended participant stays (such as full-day PK visits). Our on-site equipment includes:
Dedicated PK / Blood Draw Chairs: Ergonomic, adjustable reclining chairs designed for long-duration Pharmacokinetic (PK) day curves and frequent sampling schedules.
Laboratory & Sample Processing Setup: On-site processing area equipped with calibrated, temperature-controlled centrifuges for rapid blood, urine, and stool sample preparation.
Diagnostic & Safety Hardware: Calibrated 12-lead ECG machines, blood pressure and vital signs monitoring equipment, weight/body composition scales, and emergency response infrastructure.
Our facility in Almere is fully equipped for complex biological sample collection and handling. We routinely manage high-frequency blood sampling schedules, oral glucose tolerance tests (OGTT), urine collection, and specialized stool/feces sample processing.
For long-term biomarker and sample stability, EBMR operates two on-site -86°C Ultra-Low Temperature (ULT) freezers with continuous temperature monitoring and back-up protocols, ensuring strict GCP compliance for all biological specimens.
Because EB Medical Research is managed directly by executive decision-makers (owners/authorized signatories), we eliminate corporate bureaucracy and guarantee industry-leading turnaround times:
Feasibility Queries: Response within 16 business hours.
Budget & Proposal Requests: Response within 40 business hours.
CTA Contracting: Finalized within 80 business hours when using standard Dutch Clinical Trial Agreement (CTA) templates.
We adhere to a policy of complete transparency and realistic forecasting regarding inclusion targets and study timelines. We never over-promise on participant availability or recruitment speed, as our goal is to build long-term, repeatable partnerships with CROs and Sponsors who can rely on our commitments.
We maintain an active, GDPR-compliant participant database of approximately 4,500 candidates. This database is continuously expanded through targeted multi-channel marketing, social media campaigns, and specialized recruitment partners.
During active recruitment, our team actively monitors response metrics—analyzing communication channels, message length, and timing—to optimize conversion. As a result, EBMR is frequently recognized by sponsors as a top-performing site in the Netherlands for recruitment velocity, inclusion rates, and subject retention.
To ensure maximum transparency during study setup, EBMR applies a clear, dual-model recruitment cost structure based on your study’s recruitment funding model:
Sponsor-Funded Media / Agency Campaigns: If a Sponsor/CRO finances dedicated recruitment advertising or engages an external recruitment agency for the study, no additional fee is charged for accessing or utilizing EBMR's maintained participant database.
Standard Database Access: If no external recruitment or advertising budget is provided for the study, a fair database access and maintenance fee applies to utilize our candidate pool.
Located in the Amsterdam Metropolitan Area (Almere), EBMR offers international CROs, sponsors, and global site networks a highly efficient, high-yielding site location in Western Europe. We actively engage in multi-center international trials, strategic site-network collaborations, and long-term partnership models to expand high-quality clinical research capacity in the Netherlands.
The Netherlands is globally recognized as one of Europe’s leading hubs for life sciences and clinical research. Conducting your trial in the Netherlands offers clear strategic, operational, and structural advantages:
Proximity to the EMA & EU Regulatory Synergy: As an EU Member State using the Euro (€), the Netherlands hosts the European Medicines Agency (EMA) in Amsterdam. Clinical trial data generated in Dutch sites aligns seamlessly with EU-wide CTR (Clinical Trials Regulation) standards, facilitating smooth market authorization.
Pragmatic & Purpose-Driven Contract Law: Dutch contract law strongly emphasizes reasonableness, fairness, and mutual commercial intent rather than hyper-literal interpretations. Paired with national standardized Clinical Trial Agreement (CTA) templates, this leads to fast, efficient CTA contracting and smooth B2B collaboration.
World-Leading English Proficiency & Travel Accessibility: Ranked among the highest globally for English proficiency, the Netherlands eliminates language barriers for CRO monitors, sponsors, and auditing teams. High-speed transport and proximity to Schiphol Airport make site visits significantly more time-efficient compared to larger, geographically dispersed countries.
High Population Density & Excellent Subject Mobility: The high geographical density of the Amsterdam Metropolitan Area—paired with exceptional public transit—drives rapid participant recruitment, high enrollment velocity, and outstanding retention rates.
Uncompromising Quality & Ethical Standards: Guided by strict oversight from the Dutch Healthcare and Youth Inspectorate (IGJ) and accredited ethics committees (METC/CCMO), trial data generated at Dutch sites enjoys universal acceptance by major regulatory bodies worldwide, including the US FDA and EMA.